Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients
- PMID: 15897312
- PMCID: PMC1755506
- DOI: 10.1136/ard.2004.026377
Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients
Abstract
Background: Disseminated intravascular coagulation (DIC) is an acquired syndrome characterised by formation of microthrombi and fibrin deposition in the microvasculature. The catastrophic antiphospholipid syndrome (APS) is characterised by multiorgan thrombosis, mainly involving small vessels. A broad spectrum of disorders may develop DIC features; however, the catastrophic APS has not previously been recognised as a cause of DIC.
Objective: To analyse the clinical and laboratory characteristics of catastrophic APS patients with DIC features.
Methods: The web site based international registry of patients with catastrophic APS (CAPS registry) (http://www.med.ub.es/MIMMUN/FORUM/CAPS.HTM) was analysed and the cases with DIC features selected.
Results: In 173 patients with catastrophic APS, 23 (13%) were found with DIC features. The clinical and immunological characteristics were similar in catastrophic APS patients with and without DIC features; a significant difference was found only in the prevalence of thrombocytopenia (100% in patients with DIC features v 59% in those without DIC features).
Conclusions: DIC features are not rare in catastrophic APS, supporting the need for systematic screening of antiphospholipid antibodies in all patients with DIC features without precipitating factors. The presence of DIC features in the context of an APS makes it imperative to rule out the catastrophic variant of this syndrome.
Similar articles
-
The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients.Ann Rheum Dis. 2006 Jan;65(1):81-6. doi: 10.1136/ard.2005.037671. Epub 2005 May 26. Ann Rheum Dis. 2006. PMID: 15919677 Free PMC article.
-
Catastrophic antiphospholipid syndrome (CAPS): update from the 'CAPS Registry'.Lupus. 2010 Apr;19(4):412-8. doi: 10.1177/0961203309361353. Lupus. 2010. PMID: 20353979
-
CAPS Registry.Lupus. 2012 Jun;21(7):755-7. doi: 10.1177/0961203312436866. Lupus. 2012. PMID: 22635223
-
Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome.Immunobiology. 2005;210(10):727-33. doi: 10.1016/j.imbio.2005.10.002. Epub 2005 Oct 20. Immunobiology. 2005. PMID: 16325490 Review.
-
Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry.Autoimmun Rev. 2006 Dec;6(2):81-4. doi: 10.1016/j.autrev.2006.06.009. Epub 2006 Jul 21. Autoimmun Rev. 2006. PMID: 17138248 Review.
Cited by
-
The catastrophic antiphospholipid syndrome in Serbia: diagnostic and management problems.Clin Rev Allergy Immunol. 2009 Jun;36(2-3):98-103. doi: 10.1007/s12016-008-8102-1. Clin Rev Allergy Immunol. 2009. PMID: 19048415
-
A Case of Catastrophic Antiphospholipid Syndrome with Acute Multiorgan Thrombosis and Concerns for Re-Emergence.Am J Case Rep. 2024 Jan 28;25:e942339. doi: 10.12659/AJCR.942339. Am J Case Rep. 2024. PMID: 38281079 Free PMC article.
-
Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome.Curr Rheumatol Rep. 2010 Feb;12(1):70-6. doi: 10.1007/s11926-009-0073-6. Curr Rheumatol Rep. 2010. PMID: 20425537 Review.
-
Antiphospholipid antibodies in critically ill patients.Rev Bras Ter Intensiva. 2014 Apr-Jun;26(2):176-82. doi: 10.5935/0103-507x.20140026. Rev Bras Ter Intensiva. 2014. PMID: 25028953 Free PMC article. Review.
-
COVID-19 coagulopathy: An in-depth analysis of the coagulation system.Eur J Haematol. 2020 Dec;105(6):741-750. doi: 10.1111/ejh.13501. Epub 2020 Aug 19. Eur J Haematol. 2020. PMID: 32749010 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous